Geptanolimab

Tax included
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer.
MedChemExpress 
HY-P99639

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1
Application
Cancer-programmed cell death
CAS
2348469-43-0